Lead-time in prostate cancer screening (Finland)

[1]  R. Renzetti.  The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update , 1999 .

[2]  R. Thisted,et al.  Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.

[3]  S D Walter,et al.  Estimation of the duration of a pre-clinical disease state using screening data. , 1983, American journal of epidemiology.

[4]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[5]  T. Tammela,et al.  European randomized study of prostate cancer screening: first-year results of the Finnish trial , 1999, British Journal of Cancer.

[6]  M. Lehtonen,et al.  Data quality and quality control of a population-based cancer registry. Experience in Finland. , 1994, Acta oncologica.

[7]  J. Hugosson,et al.  Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. , 1998, The Journal of urology.

[8]  E. Feuer,et al.  Asymptomatic incidence and duration of prostate cancer. , 1998, American journal of epidemiology.

[9]  A. Whittemore,et al.  Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? , 1991, Journal of the National Cancer Institute.

[10]  P C Prorok,et al.  Lead time estimation in a controlled screening program. , 1983, American journal of epidemiology.

[11]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[12]  A S Whittemore,et al.  Prostate-specific antigen as predictor of prostate cancer in black men and white men. , 1995, Journal of the National Cancer Institute.

[13]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[14]  E. Saxén.  [Cancer incidence in Finland]. , 1962, Duodecim; laaketieteellinen aikakauskirja.

[15]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[16]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[17]  R. Kane,et al.  Observations on the early detection of prostate cancer from the American Cancer Society national prostate cancer detection project , 1997, Cancer.

[18]  Christopher H. Morrell,et al.  Estimating Unknown Transition Times Using a Piecewise Nonlinear Mixed-Effects Model in Men with Prostate Cancer , 1995 .

[19]  E. Pukkala,et al.  DATA QUALITY AND QUALITY CONTROL OF A POPULATION-BASED CANCER REGISTRY , 1994 .

[20]  P. Prorok,et al.  Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening , 1996, Journal of medical screening.